{"id":1601,"date":"2025-11-23T15:11:56","date_gmt":"2025-11-23T15:11:56","guid":{"rendered":"https:\/\/medi-pharm.sk\/pamidronat-a-kyselina-zoledronova-porovnavaci-prehlad-intravenoznych-bisfosfonatov-obsahujucich-dusik"},"modified":"2025-11-23T15:35:29","modified_gmt":"2025-11-23T15:35:29","slug":"pamidronat-a-kyselina-zoledronova-porovnavaci-prehlad-intravenoznych-bisfosfonatov-obsahujucich-dusik","status":"publish","type":"post","link":"https:\/\/medi-pharm.sk\/sk\/pamidronat-a-kyselina-zoledronova-porovnavaci-prehlad-intravenoznych-bisfosfonatov-obsahujucich-dusik","title":{"rendered":"Pamidron\u00e1t a kyselina zoledr\u00f3nov\u00e1: porovn\u00e1vac\u00ed preh\u013ead intraven\u00f3znych bisfosfon\u00e1tov obsahuj\u00facich dus\u00edk"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Pamidron\u00e1t a kyselina zoledr\u00f3nov\u00e1: porovn\u00e1vac\u00ed preh\u013ead intraven\u00f3znych bisfosfon\u00e1tov obsahuj\u00facich dus\u00edk<\/h3>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bisfosfon\u00e1ty dlhodobo predstavuj\u00fa v\u00fdznamn\u00fa terapeutick\u00fa triedu v lie\u010dbe ochoren\u00ed charakterizovan\u00fdch nadmernou resorpciou kost\u00ed. Od ich zavedenia v 70. rokoch 20. storo\u010dia transformovali lie\u010dbu metabolick\u00fdch ochoren\u00ed kost\u00ed, osteopor\u00f3zy, hyperkalc\u00e9mie s\u00favisiacej so zhubn\u00fdmi n\u00e1dormi a skelet\u00e1lnych komplik\u00e1ci\u00ed metastatick\u00e9ho ochorenia. V r\u00e1mci tejto skupiny pamidron\u00e1t a kyselina zoledr\u00f3nov\u00e1 predstavuj\u00fa dvoch z klinicky najv\u00fdznamnej\u0161\u00edch intraven\u00f3znych lie\u010div, pri\u010dom ka\u017ed\u00fd z nich formoval terapeutick\u00fa prax v r\u00f4znych obdobiach v\u00fdvoja. <\/p>

Historick\u00e9 pozadie a mechanistick\u00fd kontext<\/strong><\/p>

Bisfosfon\u00e1ty prvej gener\u00e1cie boli p\u00f4vodne uzn\u00e1van\u00e9 pre ich schopnos\u0165 inhibova\u0165 rozp\u00fa\u0161\u0165anie miner\u00e1lov, ale ich terapeutick\u00fd dopad bol skromn\u00fd. Neskor\u0161ie zavedenie bisfosfon\u00e1tov obsahuj\u00facich dus\u00edk znamenalo v\u00fdznamn\u00fd v\u00fdvoj. Tieto l\u00e1tky inhibuj\u00fa farnesylpyrofosf\u00e1t synt\u00e1zu (FPPS) v mevalon\u00e1tovej dr\u00e1he, naru\u0161uj\u00fa prenyl\u00e1ciu osteoklastov\u00fdch prote\u00ednov a v kone\u010dnom d\u00f4sledku zni\u017euj\u00fa aktivitu a pre\u017eitie osteoklastov. <\/p>

Pamidron\u00e1t, schv\u00e1len\u00fd za\u010diatkom 90. rokov, sa stal jedn\u00fdm z prv\u00fdch \u00fa\u010dinn\u00fdch IV bisfosfon\u00e1tov \u0161iroko pou\u017e\u00edvan\u00fdch pre onkologick\u00e9 indik\u00e1cie, vr\u00e1tane kostn\u00fdch metast\u00e1z a n\u00e1dorom indukovanej hyperkalc\u00e9mie. Kyselina zoledr\u00f3nov\u00e1, vyvinut\u00e1 nesk\u00f4r a uveden\u00e1 na trh za\u010diatkom 21. storo\u010dia, predstavuje \u010fal\u0161ie zdokonalenie \u0161trukt\u00fary bisfosfon\u00e1tu obsahuj\u00faceho dus\u00edk. Jemn\u00e9 \u0161truktur\u00e1lne rozdiely, vr\u00e1tane imidazolov\u00e9ho kruhu namiesto alkylov\u00e9ho bo\u010dn\u00e9ho re\u0165azca pamidron\u00e1tu, v\u00fdrazne zvy\u0161uj\u00fa jeho afinitu ku kostn\u00e9mu miner\u00e1lu a jeho inhibi\u010dn\u00fa \u00fa\u010dinnos\u0165 proti FPPS. <\/p>

Farmakokinetick\u00e9 a farmakodynamick\u00e9 \u00favahy<\/strong><\/p>

Hoci obe lie\u010div\u00e1 zdie\u013eaj\u00fa rovnak\u00fd z\u00e1kladn\u00fd mechanizmus, v\u00fdznamne sa l\u00ed\u0161ia v \u00fa\u010dinnosti, pohodlnosti d\u00e1vkovania a klinickej farmakol\u00f3gii. Pamidron\u00e1t zvy\u010dajne vy\u017eaduje pomal\u00e9 inf\u00fazie trvaj\u00face 2-4 hodiny a pod\u00e1va sa ka\u017ed\u00e9 3 t\u00fd\u017edne v onkologick\u00fdch podmienkach, zatia\u013e \u010do kyselina zoledr\u00f3nov\u00e1, s ove\u013ea vy\u0161\u0161ou FPPS-inhibi\u010dnou \u00fa\u010dinnos\u0165ou, sa pod\u00e1va ako raz ro\u010dn\u00e1 inf\u00fazia pri osteopor\u00f3ze, alebo ka\u017ed\u00e9 3-4 t\u00fd\u017edne pri ochoren\u00ed kost\u00ed spojenom so zhubn\u00fdm n\u00e1dorom, s dobou inf\u00fazie u\u017e 15 min\u00fat. Kyselina zoledr\u00f3nov\u00e1 tie\u017e preukazuje v\u00fdraznej\u0161iu supresiu markerov kostn\u00e9ho obratu, vy\u0161\u0161iu v\u00e4zbov\u00fa afinitu k hydroxyapatitu a dlh\u0161iu retenciu v skelete. Tieto rozdiely tvoria hlavn\u00e9 farmakologick\u00e9 zd\u00f4vodnenie jej terapeutickej \u00falohy ako bisfosfon\u00e1tu \u201enovej gener\u00e1cie\u201c. <\/p>

Klinick\u00e9 d\u00f4kazy a porovn\u00e1vacia \u00fa\u010dinnos\u0165<\/strong><\/p>

Klinick\u00fd prechod od pamidron\u00e1tu ku kyseline zoledr\u00f3novej sa koncep\u010dne podob\u00e1 \u201ezdokonaleniu oproti predchodcovi\u201c pozorovan\u00e9mu v in\u00fdch terapeutick\u00fdch triedach (pozri n\u00e1\u0161 \u010dl\u00e1nok o chir\u00e1lnom prepnut\u00ed omeprazol-esomeprazol). K\u013e\u00fa\u010dov\u00e9 \u0161t\u00fadie v onkol\u00f3gii a metabolick\u00fdch ochoreniach kost\u00ed preuk\u00e1zali vy\u0161\u0161iu alebo porovnate\u013en\u00fa \u00fa\u010dinnos\u0165 kyseliny zoledr\u00f3novej oproti pamidron\u00e1tu pri zni\u017eovan\u00ed skelet\u00e1lnych udalost\u00ed u pacientov s metastatick\u00fdm karcin\u00f3mom prsn\u00edka, karcin\u00f3mom prostaty alebo mnohopo\u010detn\u00fdm myel\u00f3mom, r\u00fdchlej\u0161iu a trvalej\u0161iu korekciu hyperkalc\u00e9mie pri zhubn\u00fdch n\u00e1doroch a v neposlednom rade pohodlnej\u0161ie d\u00e1vkovanie, zni\u017euj\u00face z\u00e1\u0165a\u017e lie\u010dby pri chronickej terapii. <\/p>

Av\u0161ak, rovnako ako pri porovnan\u00ed omeprazolu a esomeprazolu, obe l\u00e1tky zost\u00e1vaj\u00fa klinicky \u00fa\u010dinn\u00e9 a zdie\u013eaj\u00fa podobn\u00e9 bezpe\u010dnostn\u00e9 obavy, vr\u00e1tane rizika po\u0161kodenia obli\u010diek a osteonekr\u00f3zy \u010de\u013euste.<\/p>

Bezpe\u010dnostn\u00e9 aspekty<\/strong><\/p>

Oba lieky vy\u017eaduj\u00fa monitorovanie funkcie obli\u010diek, \u00fapravy d\u00e1vkovania a opatrn\u00e9 inf\u00fazne postupy. Ak\u00fatne reakcie, ako s\u00fa hor\u00fa\u010dka, myalgia a prechodn\u00e1 hypokalc\u00e9mia, sa m\u00f4\u017eu vyskytova\u0165 \u010dastej\u0161ie pri kyseline zoledr\u00f3novej kv\u00f4li jej silnej\u0161ej \u00fa\u010dinnosti a r\u00fdchlej\u0161iemu n\u00e1stupu \u00fa\u010dinku. <\/p>

Nov\u00e9 pr\u00edstupy<\/strong><\/p>

Po kyseline zoledr\u00f3novej nieko\u013eko inov\u00e1ci\u00ed formovalo \u201e\u010fal\u0161iu gener\u00e1ciu\u201c antiresorp\u010dnej terapie. Bisfosfon\u00e1ty \u201enovej gener\u00e1cie\u201c a preformul\u00e1cie zauj\u00edmaj\u00fa svoje miesto v modernom mana\u017emente osteopor\u00f3zy. <\/p>

Nov\u00e9 ne-bisfosfon\u00e1tov\u00e9 n\u00e1stupcovia zah\u0155\u0148aj\u00fa denosumab (inhib\u00edtor RANKL), ktor\u00fd poskytuje vynikaj\u00facu ochranu pred zlomeninami v niektor\u00fdch pr\u00edpadoch, romosozumab (inhib\u00edtor sklerost\u00ednu) s anabolick\u00fdm a antiresorp\u010dn\u00fdm du\u00e1lnym \u00fa\u010dinkom a selekt\u00edvne inhib\u00edtory kateps\u00ednu K, ktor\u00e9 cielia na osteoklastmi sprostredkovan\u00fa resorpciu kost\u00ed blokovan\u00edm enz\u00fdmu zodpovedn\u00e9ho za degrad\u00e1ciu kolag\u00e9nu. Tieto alternat\u00edvy \u010doraz viac konkuruj\u00fa bisfosfon\u00e1tom a formuj\u00fa bud\u00face terapeutick\u00e9 prostredie, ale bisfosfon\u00e1ty na\u010falej dominuj\u00fa tam, kde s\u00fa k\u013e\u00fa\u010dov\u00e9 n\u00e1kladov\u00e1 efekt\u00edvnos\u0165 a dlhodob\u00e1 bezpe\u010dnos\u0165. <\/p>

V\u00fdznam pre MediPharm<\/strong><\/p>

Toto porovnanie pamidron\u00e1tu a kyseliny zoledr\u00f3novej poukazuje na \u0161ir\u0161iu t\u00e9mu relevantn\u00fa pre modern\u00fd farmaceutick\u00fd v\u00fdvoj: dokonca aj inkrement\u00e1lne molekul\u00e1rne zdokonalenie m\u00f4\u017ee prinies\u0165 klinicky a komer\u010dne v\u00fdznamn\u00e9 zlep\u0161enia, najm\u00e4 v chronickej alebo podpornej starostlivosti.<\/p>

Pre MediPharm tento terapeutick\u00fd p\u00e1r ilustruje typ komplexn\u00fdch, na stabilitu citliv\u00fdch, parenter\u00e1lnych formul\u00e1ci\u00ed, ktor\u00e9 s\u00fa v s\u00falade s mo\u017enos\u0165ami spolo\u010dnosti, vr\u00e1tane v\u00fdroby v s\u00falade s GMP, odborn\u00fdch znalost\u00ed v sterilnej v\u00fdrobe a lyofiliz\u00e1cii, sk\u00fasenost\u00ed s dod\u00e1vkami mal\u00fdch \u0161ar\u017e\u00ed a pre klinick\u00e9 sk\u00fa\u0161ky, schopnosti podporova\u0165 optimaliz\u00e1ciu zaveden\u00fdch injek\u010dn\u00fdch terapi\u00ed a robustn\u00fdch r\u00e1mcov pre analytick\u00e9 testovanie a testovanie stability.<\/p>

Ke\u010f\u017ee zdravotn\u00edcke syst\u00e9my sa na\u010falej spoliehaj\u00fa na biofarmaceutik\u00e1, ktor\u00e9 vy\u017eaduj\u00fa vysokokvalitn\u00fa parenter\u00e1lnu v\u00fdrobu, MediPharm je pripraven\u00fd podporova\u0165 partnerov v oblasti zaveden\u00fdch bisfosfon\u00e1tov\u00fdch terapi\u00ed aj preformul\u00e1ci\u00ed novej gener\u00e1cie, vr\u00e1tane \u0161t\u00fadi\u00ed uskuto\u010dnite\u013enosti, zlep\u0161enia formul\u00e1ci\u00ed a klinickej v\u00fdroby.<\/p>

Zdroje:<\/strong><\/pre>

Rosen, L.S. et al. (2001) \u201eKyselina zoledr\u00f3nov\u00e1 verzus pamidron\u00e1t v lie\u010dbe skelet\u00e1lnych metast\u00e1z u pacientov s karcin\u00f3mom prsn\u00edka alebo mnohopo\u010detn\u00fdm myel\u00f3mom: f\u00e1za III, dvojito zaslepen\u00e1, komparat\u00edvna \u0161t\u00fadia\u201c, Cancer, 91(7), pp. 1191-1200.<\/em>

Major, P. et al. (2001) \u201eKyselina zoledr\u00f3nov\u00e1 je lep\u0161ia ako pamidron\u00e1t na lie\u010dbu hyperkalc\u00e9mie pri zhubn\u00fdch n\u00e1doroch: randomizovan\u00e1, kontrolovan\u00e1 klinick\u00e1 \u0161t\u00fadia\u201c, Journal of Clinical Oncology, 19(2), pp. 558-567.<\/em>

Black, D.M. a Rosen, C.J. (2016) \u201eKlinick\u00e1 prax: postmenopauz\u00e1lna osteopor\u00f3za\u201c, New England Journal of Medicine, 374(3), pp. 254-262.<\/em><\/pre>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"
Bisfosfon\u00e1ty dlhodobo predstavuj\u00fa v\u00fdznamn\u00fa terapeutick\u00fa triedu v lie\u010dbe ochoren\u00ed charakterizovan\u00fdch nadmernou resorpciou kost\u00ed. Od ich zavedenia v 70. rokoch 20. storo\u010dia transformovali lie\u010dbu metabolick\u00fdch ochoren\u00ed kost\u00ed, osteopor\u00f3zy, hyperkalc\u00e9mie s\u00favisiacej so zhubn\u00fdmi n\u00e1dormi a skelet\u00e1lnych komplik\u00e1ci\u00ed metastatick\u00e9ho ochorenia. V r\u00e1mci tejto skupiny pamidron\u00e1t a kyselina zoledr\u00f3nov\u00e1 predstavuj\u00fa dvoch z klinicky najv\u00fdznamnej\u0161\u00edch intraven\u00f3znych lie\u010div, pri\u010dom ka\u017ed\u00fd z […]<\/p>\n","protected":false},"author":1,"featured_media":1600,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-1601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-sk"],"_links":{"self":[{"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/posts\/1601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/comments?post=1601"}],"version-history":[{"count":2,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/posts\/1601\/revisions"}],"predecessor-version":[{"id":1607,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/posts\/1601\/revisions\/1607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/media\/1600"}],"wp:attachment":[{"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/media?parent=1601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/categories?post=1601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medi-pharm.sk\/sk\/wp-json\/wp\/v2\/tags?post=1601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}